



[Optovue, Inc.](#) is a privately held medical device company working closely with eye care professionals and clinical researchers around the world to lead the development and commercialization of high-speed Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) instruments. These diagnostic tools are used to facilitate the visualization and management of eye diseases.

In 2003, Jay Wei founded the company to develop the next generation of ophthalmic OCT instruments to help clinicians improve the quality of life of their patients. OCT technology utilizes light waves to rapidly form detailed, three-dimensional images of anatomical structures in the eye with micrometer resolution. His concept for the clinical use of OCT technology resulted in the first FDA-cleared Fourier-domain (spectral domain) SD-OCT system, the RTVue®.

Today, Optovue is the global leader in the development and commercialization of OCT and OCTA. The company's high-speed, high-resolution SD-OCT technology provides physicians with advanced ocular imaging capabilities essential for helping diagnose and manage retinopathy, optic nerve head and other macular diseases, as well as anterior segment diseases.

Optovue is the first company to develop and commercialize the pioneering [OCTA technology](#), which provides clinicians with information about the blood flow in retinal vessels – the light sensitive tissue lining the back of the eye.

The company's proprietary OCTA instrument, the [AngioVue® Imaging System](#), embodies a non-invasive, dyeless technique for quickly visualizing the presence or absence of flow in the blood vessels, as well as abnormal blood vessel growth. In seconds, the AngioVue System acquires images that complement the current angiography imaging standard, fluorescein angiography (FA), but with a number of advantages. As a result, physicians are able to analyze this new information from the microvasculature and perfusion in ocular diseases with extraordinary detail, which may help to determine the best course of treatment for each patient.

Dedicated to expanding the frontiers of OCT innovation and ophthalmic medical diagnostic imaging through helping to improve both the diagnosis and management of ocular diseases, Optovue hopes to significantly improve accessibility to this vision saving technology for patients around the world.

To date, there are over 650 peer-reviewed publications detailing the AngioVue OCTA Imaging technology and clinical applications. The company has installed over 12,000 products worldwide. For more information, visit www.optovue.com.

###

Media Contact:

Christina Kirby
Christina_kirby@optovue.com